Cargando…
Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
BACKGROUND: TP53, encoding the tumor suppressor p53, is frequently mutated in various cancers, producing mutant p53 proteins (mutp53) which can exhibit neomorphic, gain-of-function properties. The latter transform p53 into an oncoprotein that promotes metastatic tumor progression via downstream effe...
Autores principales: | Pavlakis, Evangelos, Neumann, Michelle, Merle, Nastasja, Wieboldt, Ronja, Wanzel, Michael, Ponath, Viviane, Pogge von Strandmann, Elke, Elmshäuser, Sabrina, Stiewe, Thorsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413714/ https://www.ncbi.nlm.nih.gov/pubmed/37563605 http://dx.doi.org/10.1186/s13046-023-02785-z |
Ejemplares similares
-
Beyond the Extracellular Vesicles: Technical Hurdles, Achieved Goals and Current Challenges When Working on Adipose Cells
por: Gómez-Serrano, María, et al.
Publicado: (2021) -
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
por: Gremke, Niklas, et al.
Publicado: (2020) -
The Number and Location of Glycans on Influenza Hemagglutinin Determine Folding and Association with Calnexin and Calreticulin
por: Hebert, Daniel N., et al.
Publicado: (1997) -
Substrate Specificity of the Oxidoreductase ERp57 Is Determined Primarily
by Its Interaction with Calnexin and
Calreticulin
por: Jessop, Catherine E., et al.
Publicado: (2009) -
KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP
por: Alkhayer, Reem, et al.
Publicado: (2023)